CA-SYNACK
13.6.2019 15:02:06 CEST | Business Wire | Press release
The debate on how we should best use Artificial Intelligence is ongoing, but no one can argue against its benefits when used to augment human work. Take self-driving cars: when Artificial Intelligence is used alongside humans, it provides features like improved safety and predictive driving. The same is true in cybersecurity; we will always need the creativity of human intelligence to beat the human adversary. However, we can also augment those humans with smart technology to help make them more effective, cover a wider attack surface, and speed up their time to find and fix vulnerabilities. Synack, the trusted leader in crowdsourced security, has just launched the industry’s first cybersecurity platform to integrate crowdsourced human intelligence augmented with artificial intelligence to help security teams work smarter, not harder, to protect digital assets continuously and at scale.
The impact? Intelligence that helps security teams find and fix vulnerabilities faster and build more secure code.
The stakes are high - cybercrime is predicted to cost the world $6 trillion annually by 2021- and human capital to protect the cybersphere is lacking; 3.5 million cybersecurity jobs are predicted to go unfilled by 2021 (Cybersecurity Ventures).
“While humans can’t scale, machines can’t think. More than 80% of the vulnerabilities that our Synack Red Team find in our clients’ assets aren’t detected by a scanner. We will always need the creativity of human intelligence. But to scale at the pace of the threats, we need to automate wherever possible and keep building technology to test ‘smarter’,” Dr. Mark Kuhr, Synack CTO and co-founder said.
Synack’s industry-leading cybersecurity Platform 2.0 delivers a smarter, more efficient security test through the use of smart platform technology and new product, SmartScan. Together, the platform’s new features and advanced technology seamlessly orchestrate the optimal combination of human and machine intelligence for more effective, efficient security on a 24/7/365 basis. SmartScan helps security teams increase their attack surface coverage and gain new insight by continuously scanning for suspected vulnerabilities and engaging the company’s crowdsourced network of ethical hackers to validate them. The augmented intelligence offered by Synack’s “smart” Crowdsourced Security Platform, if applied to all penetration testing, would add 4x more efficiency to security teams.
Additional benefits of Synack’s Crowdsourced Security Platform to security teams include:
- Noise Reduction: 99.98% of total noise is reduced by leveraging Synack SmartScan in combination with Synack Red Team crowdsourced vulnerability triage and patch verification services.
- Higher Value: The latest version of Synack’s platform with augmented intelligence increases the ROI of Synack’s original offering by over 50%. Customers will see a 159% ROI with the Synack Crowdsourced Security Platform in comparison to a traditional penetration test. And if comparing the Synack platform to a traditional scanner, they will get a 262% ROI. If deployed universally across application security testing, SmartScan would add ~$3B in security value back to the market.
In addition to SmartScan, Synack’s Crowdsourced Security Platform 2.0 includes other new and enhanced features; Apollo, a machine learning and automation engine that optimizes the integration of humans and technology, superior analytics and reporting, and LaunchPoint+, a secure testing gateway with added researcher endpoint control and enhanced workspaces to support privacy for highly regulated environments. Synack Red Team researchers said they were “happy with the [LaunchPoint+] concept”, “a fan of the increased bandwidth”, and could “definitely see myself using this a lot” in response to Synack launching the only crowdsourced security testing with endpoint control baked into the platform.
About Synack
Synack, the most trusted crowdsourced security platform, delivers continuous and scalable penetration testing with actionable results. The company combines the world's most skilled and trusted ethical hackers with AI-enabled technology to create an efficient and effective security solution. Headquartered in Silicon Valley with regional offices around the world, Synack protects leading global banks, federal agencies, DoD classified assets, and close to $1 trillion in Fortune 500 revenue. Synack was founded in 2013 by former US Department of Defense hackers Jay Kaplan, CEO, and Dr. Mark Kuhr, CTO. For more information, please visit www.synack.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190613005222/en/
Contact:
Ellie McCardwell, Synack Communications press@synack.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
